{"doc_id": "si-2020-0654-reg-1", "parent_doc_id": "si-2020-0654", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "1. These Regulations may be cited as the Health Products Regulatory", "text_raw": "1. These Regulations may be cited as the Health Products Regulatory \n\nAuthority (Fees) Regulations 2020.", "text_norm": "1 regulation may cited health product regulatory authority (fees) regulation 2020", "start_char": 594, "end_char": 701, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-reg-2", "parent_doc_id": "si-2020-0654", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Act of 1995” means the Irish Medicines Board Act 1995 (No. 29 of 1995); \n\n“Act of 2006” means the Irish Medicines Board (Miscellaneous Provisions) \nAct 2006 (No. 3 of 2006); \n\n“active substances register” has the meaning assigned to it by Regulation 3(1) \n(inserted by Regulation 3(a) of \nthe Medicinal Products (Control of \nManufacture) (Amendment) Regulations 2013 (S.I. No. 163 of 2013)) of the \nMedicinal Products (Control of Manufacture) Regulations 2007 (S.I. No. 539 \nof 2007); \n\n“authorised representative” – \n\n(a) means a person established within the European Economic Area \nwho, explicitly designated by the manufacturer, acts for the \nmanufacturer and may be addressed by authorities and bodies in \nthe European Economic Area instead of the manufacturer with \nrespect to the European Communities (Medical Devices) \nRegulations 1994 (S.I. No. 252 of 1994), the European \nImplantable Medical Devices) \nCommunities \nRegulations 1994 (S.I. No. 253 of 2004), or the European \nCommunities \n(In Vitro Diagnostic Medical Devices) \nRegulations 2001 (S.I. No. 304 of 2001), \n\n(Active \n\n(b) has the meaning assigned to it by Article 2(32) of Regulation \n(EU) 2017/745 of the European Parliament and of the Council \nof 5 April 2017 1, \n\n1 OJ L117, 5.5.2017, p.1 \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 1st January, 2021. \n\n \n \n \n \n \n \n \n \n \n \n\f[654] 3 \n\n(c) has the meaning assigned to it by Article 2(25) of Regulation \n(EU) 2017/746 of the European Parliament and of the Council \nof 5 April 20172; \n\n“Authority” means the Health Products Regulatory Authority; \n\n“breeder authorisation” has the meaning assigned to it by Regulation 3(1) of \nthe Protection of Animals Regulations; \n\n“broker” means a person carrying out the brokering of medicinal products, as \ndefined in Regulation 4(1) (as amended by Regulation 3(a) of the Medicinal \nProducts (Control of Wholesale Distribution) (Amendment) Regulations 2013 \n(S.I. No. 164 of 2013)) of the Control of Wholesale Distribution Regulations; \n\n“brokers register” has the meaning assigned to it by Regulation 4(1) (as \namended by Regulation 3(a) of the Medicinal Products (Control of Wholesale \nDistribution) (Amendment) Regulations 2013 (S.I. No. 164 of 2013)) of the \nControl of Wholesale Distribution Regulations; \n\n“certificate of free sale” means – \n\n(a) \n\n(b) \n\n(c) \n\na certificate of free sale issued under section 4(1)(k)(ii) (as \namended by section 11(a)(iii) of the Act of 2006) of the Act of \n1995, or \n\na certificate of free sale issued under Article 60 of Regulation \n(EU) 2017/745 of the European Parliament and of the Council \nof 5 April 20173, or \n\na certificate of free sale issued under Article 55 of Regulation \n(EU) 2017/746 of the European Parliament and of the Council \nof 5 April 20174; \n\n“certificate of registration” has the meaning assigned to it by Regulation 3(1) \nof the Control of Placing on the Market Regulations; \n\n“certificate of traditional-use registration” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n2 OJ L117, 5.5.2017, p.176 \n3 OJ L117, 5.5.2017, p.1 \n4 OJ L117, 5.5.2017, p.176 \n\n \n \n \n \n \n \n \n \n \n \n\f4 [654] \n\n“certification of documents” means the certification, under section 4(1)(k)(ii) \n(as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995, of \ndocuments not being certificates of free sale or export certificates; \n\n“complex dossier” refers to an application accompanied by a full dossier in \naccordance with Directive 2001/83/EC; \n\n“Control of Placing on the Market Regulations” means the Medicinal Products \n(Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of 2007); \n\n“Control of Wholesale Distribution Regulations” means the Medicinal \nProducts (Control of Wholesale Distribution) Regulations 2007 (S.I. No. 538 \nof 2007); \n\n“decentralised procedure” means the decentralised procedure for human \nmedicinal products provided for in Directive 2001/83/EC; \n\n“Directive 2001/83/EC” means Directive 2001/83/EC of the European \nParliament and of the Council of 6 November 20015; \n\n“distributor”, in the context of medical devices, means any natural or legal \nperson in the supply chain, other than the manufacturer or the importer, that \nmakes a device available on the market, up until the point of putting into \nservice; \n\n“listed organisation” has the meaning assigned to it by Regulation 4(1) (as \namended by Regulation 3 of the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 2) Regulations 2015 (S.I. No. 449 of 2015)) of \nthe Medicinal Products (Prescription and Control of Supply) Regulations 2003 \n(S.I. No. 540 of 2003); \n\n“export certificate” means an export certificate issued under section 4(1)(k)(ii) \n(as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995; \n\n“follow-up inspections” means inspections other than routine inspections; \n\n“homeopathic medicinal product” has the meaning assigned to it by Regulation \n3(1) of the Control of Placing on the Market Regulations; \n\n5 OJ No. L 311, 28.11.2001, p. 67. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[654] 5 \n\n“importer”, in the context of medical devices, means any natural or legal \nperson established within the Union that places a device from a third country \non the Union market; \n\n“individual authorisation” means an authorisation granted to an individual \nunder Part 8 of the Protection of Animals Regulations; \n\n“investigational medicinal product” has the meaning assigned to it by \nRegulation 3(1) of \nthe Medicinal Products (Control of Manufacture) \nRegulations 2007; \n\n“manufacturer”, in the context of medical devices, \n\n(a) means— \n\n(i) \n\na person who is responsible for the design, manufacture, \npackaging and labelling of a medical device before it is \nplaced on the market under his or her own name, \nregardless of whether these operations are carried out by \nthat person himself or herself or on his or her behalf by a \nthird party, or \n\n(ii) a person who assembles, packages, processes, fully \nrefurbishes or labels one or more ready-made products or \nassigns to them their intended purpose as a medical device \nwith a view to their being placed on the market under his \nor her own name, but not including a person who \nassembles or adapts medical devices already on the market \nto their intended purpose for an individual patient, or \n\n(b) has the meaning assigned to it by- \n\n(i) Article 2(30) of Regulation (EU) 2017/745 of the \nEuropean Parliament and of the Council of 5 April 20176, \nor \n\n(ii) Article 2(23) of Regulation (EU) 2017/746 of \n\nthe \nEuropean Parliament and of the Council of 5 April 20177; \n\n“manufacturer’s authorisation” has the meaning assigned to it by Regulation \n3(1) of the Medicinal Products (Control of Manufacture) Regulations 2007; \n\n“manufacturing facility”, in the context of medical devices, means a place \nwhere an entity, which does not place medical devices on the market under its \nown name or under its own trademark— \n\n6 OJ L117, 5.5.2017, p.1 \n7 OJ L117, 5.5.2017, p.176 \n\n \n \n \n \n \n \n \n \n\f6 [654] \n\n(a) manufactures a medical device, or \n\n(b) manufactures one or more critical components of a medical \n\ndevice to a set of specifications, or \n\n(c) \n\ncarries out packaging activities in relation to a medical device, \nor \n\n(d) \n\ncarries out labelling activities in relation to a medical device; \n\n“marketing authorisation” means a marketing authorisation granted pursuant to \nthe Control of Placing on the Market Regulations; \n\n“medical device” \n\n(a) means any instrument, apparatus, appliance, material or other \narticle, whether used alone or in combination, including the \nsoftware necessary for its proper application intended by the \nmanufacturer to be used for human beings for the purpose of: \n\n- diagnosis, prevention, monitoring, treatment or alleviation of \ndisease, \n\n- diagnosis, monitoring, \ncompensation for an injury or handicap, \n\ntreatment, alleviation of or \n\n- investigation, replacement or modification of the anatomy or \nof a physiological process, \n\n- control of conception, \n\nand which does not achieve its principal intended action in or on the \nhuman body by pharmacological, immunological or metabolic means, \nbut which may be assisted in its function by such means; \n\n(b) or has the meaning assigned to it by Article 2(1) of Regulation \n(EU) 2017/745 of the European Parliament and of the Council \nof 5 April 20178; \n\n(c) or has the meaning assigned to “device” by Regulation 2 (1) of \nthe European Communities (Medical Devices) Regulations, \n1994 (SI 252/1994) which transposed Directive 93/42/EEC of \n14th June 1993 into Irish Law \n\n(d) or has the meaning assigned to “device” by Regulation 2 (1) of \nthe European Communities (Active Implantable Medical \nDevices) Regulations, 1994 (SI 253/1994) which transposed \nDirective 90/385/EEC of 20th June 1990 into Irish Law \n\n(e) or has the meaning assigned to “device” by Regulation 2 (1) of \nthe European Communities (In Vitro Diagnostic Medical \n(S.I. No. 304/2001) which \nDevices) Regulations, 2001 \n\n8 OJ L117, 5.5.2017, p.1 \n\n \n \n \n \n \n\f[654] 7 \n\ntransposed Directive 98/79/EC of the European Parliament and \nof the Council of 27 October 19989 into Irish law \n\n(f) \n\nor has the meaning assigned to it by Article 2(2) of Regulation \n(EU) 2017/746 of the European Parliament and of the Council \nof 5 April 201710; \n\n“mutual recognition procedure” means the mutual recognition procedure for \nhuman medicinal products provided for in Directive 2001/83/EC; \n\n“national rules scheme” means the national rules governing the granting of \nmarketing authorisation in respect of homeopathic medicinal products, as \nprovided in Regulation 11 of the Control of Placing on the Market Regulations; \n\n“notified body”- \n\nthat \n\ntask \n\n(a) means, in relation to any task, a body designated and notified in \nthe European \nrespect of \nCommunities \nthe \nEuropean Communities (Active Implantable Medical Devices) \nRegulations 1994, or the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001, or \n\nin accordance with \n(Medical Devices) Regulations 1994, \n\n(b) has the meaning assigned to it by Article 2(42) of Regulation \n(EU) 2017/745 of the European Parliament and of the Council \nof 5 April 201711, or \n\n(c) has the meaning assigned to it by Article 2(34) of Regulation \n(EU) 2017/746 of the European Parliament and of the Council \nof 5 April 201712; \n\n“organ establishment authorisation” means an authorisation granted pursuant to \nRegulation 6 of the European Union (Quality and Safety of Human Organs \nIntended for Transplantation) Regulations 2012 (S.I. No. 325 of 2012); \n\n“parallel import licence” has the meaning assigned to it by Regulation 3(1) of \nthe Control of Placing on the Market Regulations; \n\n“project” and “project authorisation” have the meanings assigned to them by \nRegulation 3(1) of the Protection of Animals Regulations; \n\n9 OJ L331, 7.12.1998, p.1 \n10 OJ L117, 5.5.2017, p.176 \n11 OJ L117, 5.5.2017, p.1 \n12 OJ L117, 5.5.2017, p.176 \n\n \n \n \n \n \n \n \n \n \n\f8 [654] \n\n“Protection of Animals Regulations” means the European Union (Protection of \nAnimals used for Scientific Purposes) Regulations 2012 (S.I. No. 543 of 2012); \n\n“reduced dossier – complex” refers to an application for a generic medicinal \nproduct accompanied by a reduced dossier but containing additional data in \ncircumstances required by Directive 2001/83/EC; \n\n“reduced dossier – standard” refers to an application for a generic medicinal \nproduct accompanied by a reduced dossier in accordance with Directive \n2001/83/EC; \n\n“service item” means an application for a medicinal product designated by the \nAuthority as qualifying for a reduced application fee on the basis that the \nproduct has limited but important uses for which no alternative authorised \nproduct exists; \n\n“subsequent extension applications” means applications \nto \nadditional pharmaceutical forms and strengths of a medicinal product, made \nsubsequent to the first application in relation to that product; \n\nin relation \n\n“supplier authorisation” has the meaning assigned to it by Regulation 3(1) of \nthe Protection of Animals Regulations; \n\n“switching applications” means applications for a change in the classification \nof medicinal products under Title VI of Directive 2001/83/EC; \n\n“traditional herbal medicinal product” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“type IA variation”, “type IB variation” and “type II standard variation” refer \nto classifications by the Authority in accordance with Commission Regulation \n(EC) No. 1234/2008 of 24 November 200813; \n\n“user authorisation” has the meaning assigned to it by Regulation 3(1) of the \nProtection of Animals Regulations; \n\n“wholesaler’s authorisation” has the meaning assigned to it by Regulation 4(1) \nof the Medicinal Products (Control of Wholesale Distribution) Regulations", "text_norm": "2 regulations-- act 1995 mean irish medicine board act 1995 (no 29 1995) act 2006 mean irish medicine board (miscellaneous provisions) act 2006 (no 3 2006) active substance register meaning assigned regulation 3(1) (inserted regulation 3(a) medicinal product (control manufacture) (amendment) regulation 2013 (s.i no 163 2013)) medicinal product (control manufacture) regulation 2007 (s.i no 539 2007) authorised representative - (a) mean person established within european economic area explicitly designated manufacturer act manufacturer may addressed authority body european economic area instead manufacturer respect european community (medical devices) regulation 1994 (s.i no 252 1994) european implantable medical devices) community regulation 1994 (s.i no 253 2004) european community (in vitro diagnostic medical devices) regulation 2001 (s.i no 304 2001) (active (b) meaning assigned article 2(32) regulation (eu) 2017 745 european parliament council 5 april 2017 1 1 oj l117 5.5.2017 p.1 notice making statutory instrument published iris oifigiuil 1st january 2021 654 3 (c) meaning assigned article 2(25) regulation (eu) 2017 746 european parliament council 5 april 20172 authority mean health product regulatory authority breeder authorisation meaning assigned regulation 3(1) protection animal regulation broker mean person carrying brokering medicinal product defined regulation 4(1) (as amended regulation 3(a) medicinal product (control wholesale distribution) (amendment) regulation 2013 (s.i no 164 2013)) control wholesale distribution regulation broker register meaning assigned regulation 4(1) (as amended regulation 3(a) medicinal product (control wholesale distribution) (amendment) regulation 2013 (s.i no 164 2013)) control wholesale distribution regulation certificate free sale mean - (a) (b) (c) certificate free sale issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 certificate free sale issued article 60 regulation (eu) 2017 745 european parliament council 5 april 20173 certificate free sale issued article 55 regulation (eu) 2017 746 european parliament council 5 april 20174 certificate registration meaning assigned regulation 3(1) control placing market regulation certificate traditional-use registration meaning assigned regulation 3(1) control placing market regulation 2 oj l117 5.5.2017 p.176 3 oj l117 5.5.2017 p.1 4 oj l117 5.5.2017 p.176 4 654 certification document mean certification section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 document certificate free sale export certificate complex dossier refers application accompanied full dossier accordance directive 2001 83 ec control placing market regulation mean medicinal product (control placing market) regulation 2007 (s.i no 540 2007) control wholesale distribution regulation mean medicinal product (control wholesale distribution) regulation 2007 (s.i no 538 2007) decentralised procedure mean decentralised procedure human medicinal product provided directive 2001 83 ec directive 2001 83 ec mean directive 2001 83 ec european parliament council 6 november 20015 distributor context medical device mean natural legal person supply chain manufacturer importer make device available market point putting service listed organisation meaning assigned regulation 4(1) (as amended regulation 3 medicinal product (prescription control supply) (amendment) (no 2) regulation 2015 (s.i no 449 2015)) medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) export certificate mean export certificate issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 follow-up inspection mean inspection routine inspection homeopathic medicinal product meaning assigned regulation 3(1) control placing market regulation 5 oj no l 311 28.11.2001 p 67 654 5 importer context medical device mean natural legal person established within union place device third country union market individual authorisation mean authorisation granted individual part 8 protection animal regulation investigational medicinal product meaning assigned regulation 3(1) medicinal product (control manufacture) regulation 2007 manufacturer context medical device (a) means-- (i) person responsible design manufacture packaging labelling medical device placed market name regardless whether operation carried person behalf third party (ii) person assembles package process fully refurbishes label one ready-made product assigns intended purpose medical device view placed market name including person assembles adapts medical device already market intended purpose individual patient (b) meaning assigned by- (i) article 2(30) regulation (eu) 2017 745 european parliament council 5 april 20176 (ii) article 2(23) regulation (eu) 2017 746 european parliament council 5 april 20177 manufacturer authorisation meaning assigned regulation 3(1) medicinal product (control manufacture) regulation 2007 manufacturing facility context medical device mean place entity place medical device market name trademark-- 6 oj l117 5.5.2017 p.1 7 oj l117 5.5.2017 p.176 6 654 (a) manufacture medical device (b) manufacture one critical component medical device set specification (c) carry packaging activity relation medical device (d) carry labelling activity relation medical device marketing authorisation mean marketing authorisation granted pursuant control placing market regulation medical device (a) mean instrument apparatus appliance material article whether used alone combination including software necessary proper application intended manufacturer used human being purpose - diagnosis prevention monitoring treatment alleviation disease - diagnosis monitoring compensation injury handicap treatment alleviation - investigation replacement modification anatomy physiological process - control conception achieve principal intended action human body pharmacological immunological metabolic mean may assisted function mean (b) meaning assigned article 2(1) regulation (eu) 2017 745 european parliament council 5 april 20178 (c) meaning assigned device regulation 2 (1) european community (medical devices) regulation 1994 (si 252 1994) transposed directive 93 42 eec 14th june 1993 irish law (d) meaning assigned device regulation 2 (1) european community (active implantable medical devices) regulation 1994 (si 253 1994) transposed directive 90 385 eec 20th june 1990 irish law (e) meaning assigned device regulation 2 (1) european community (in vitro diagnostic medical (s.i no 304 2001) devices) regulation 2001 8 oj l117 5.5.2017 p.1 654 7 transposed directive 98 79 ec european parliament council 27 october 19989 irish law (f) meaning assigned article 2(2) regulation (eu) 2017 746 european parliament council 5 april 201710 mutual recognition procedure mean mutual recognition procedure human medicinal product provided directive 2001 83 ec national rule scheme mean national rule governing granting marketing authorisation respect homeopathic medicinal product provided regulation 11 control placing market regulation notified body - task (a) mean relation task body designated notified european respect community european community (active implantable medical devices) regulation 1994 european community (in vitro diagnostic medical devices) regulation 2001 accordance (medical devices) regulation 1994 (b) meaning assigned article 2(42) regulation (eu) 2017 745 european parliament council 5 april 201711 (c) meaning assigned article 2(34) regulation (eu) 2017 746 european parliament council 5 april 201712 organ establishment authorisation mean authorisation granted pursuant regulation 6 european union (quality safety human organ intended transplantation) regulation 2012 (s.i no 325 2012) parallel import licence meaning assigned regulation 3(1) control placing market regulation project project authorisation meaning assigned regulation 3(1) protection animal regulation 9 oj l331 7.12.1998 p.1 10 oj l117 5.5.2017 p.176 11 oj l117 5.5.2017 p.1 12 oj l117 5.5.2017 p.176 8 654 protection animal regulation mean european union (protection animal used scientific purposes) regulation 2012 (s.i no 543 2012) reduced dossier - complex refers application generic medicinal product accompanied reduced dossier containing additional data circumstance required directive 2001 83 ec reduced dossier - standard refers application generic medicinal product accompanied reduced dossier accordance directive 2001 83 ec service item mean application medicinal product designated authority qualifying reduced application fee basis product limited important us alternative authorised product exists subsequent extension application mean application additional pharmaceutical form strength medicinal product made subsequent first application relation product relation supplier authorisation meaning assigned regulation 3(1) protection animal regulation switching application mean application change classification medicinal product title vi directive 2001 83 ec traditional herbal medicinal product meaning assigned regulation 3(1) control placing market regulation type ia variation type ib variation type ii standard variation refer classification authority accordance commission regulation (ec) no 1234 2008 24 november 200813 user authorisation meaning assigned regulation 3(1) protection animal regulation wholesaler authorisation meaning assigned regulation 4(1) medicinal product (control wholesale distribution) regulation", "start_char": 701, "end_char": 13675, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-reg-2007", "parent_doc_id": "si-2020-0654", "section_id": "reg-2007", "section_label": "Regulation 2007.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "13 OJ No. L 334, 12.12.2008, p. 7.", "text_raw": "2007. \n\n13 OJ No. L 334, 12.12.2008, p. 7. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[654] 9", "text_norm": "2007 13 oj no l 334 12.12.2008 p 7 654 9", "start_char": 13675, "end_char": 13755, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-reg-3", "parent_doc_id": "si-2020-0654", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "3. Subject to Regulation 4, there shall be paid to the Authority in respect", "text_raw": "3. Subject to Regulation 4, there shall be paid to the Authority in respect \nof each and every matter set out in column 1 of the Schedule the corresponding \nfee set out in column 2 of the Schedule.", "text_norm": "3 subject regulation 4 shall paid authority respect every matter set column 1 schedule corresponding fee set column 2 schedule", "start_char": 13755, "end_char": 13955, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-reg-4", "parent_doc_id": "si-2020-0654", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "4. The Authority may, in circumstances where it considers it appropriate", "text_raw": "4. The Authority may, in circumstances where it considers it appropriate \nto do so, waive, remit or refund, either in whole or in part, any fee that would \notherwise be payable to it under Regulation 3.", "text_norm": "4 authority may circumstance considers appropriate waive remit refund either whole part fee would otherwise payable regulation 3", "start_char": 13955, "end_char": 14160, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-reg-5", "parent_doc_id": "si-2020-0654", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "5. The Health Products Regulatory Authority (Fees) Regulations 2019", "text_raw": "5. The Health Products Regulatory Authority (Fees) Regulations 2019 \n\n(S.I. No. 700 of 2019) are revoked. \n\n \n \n \n \n \n\f10 [654]", "text_norm": "5 health product regulatory authority (fees) regulation 2019 (s.i no 700 2019) revoked 10 654", "start_char": 14160, "end_char": 14290, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-schedule", "parent_doc_id": "si-2020-0654", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "COLUMN 1", "text_raw": "SCHEDULE \n\nCOLUMN 1 \n\n COLUMN 2 \n\nFees for national applications for marketing authorisations \n\n € \n\nComplex dossier \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – complex \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – standard \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nSubsequent extension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\n20,400 \n\n7,140 \n\n1,020 \n\n4,080 \n\n15,300 \n\n7,140 \n\n1,020 \n\n4,080 \n\n10,200 \n\n7,140 \n\n1,020 \n\n4,080 \n\n10,200 \n\n7,140 \n\n3,060 \n\n1,020 \n\n4,080 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\fFees for applications for marketing authorisations using mutual \nrecognition procedure and decentralised procedure \n\nComplex dossier \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \nMember States \n\nReduced dossier – complex \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \nMember States \n\n[654] 11 \n\n14,280 \n\n5,100 \n\n1,020 \n\n15,300 \n\n15,300 \n\n20,400 \n\n51,000 \n\n7,140 \n\n1,020 \n\n1,530 \n\n10,200 \n\n5,100 \n\n1,020 \n\n15,300 \n\n10,200 \n\n15,300 \n\n40,800 \n\n7,140 \n\n1,020 \n\n1,530 \n\n \n \n \n \n \n \n \n\f12 [654] \n\nReduced dossier – standard \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \nMember States \n\nSubsequent extension applications \n\nMutual recognition incoming (first additional form) \n\nMutual recognition incoming (first additional strength) \n\nMutual recognition incoming (subsequent additional strength) \n\nOutgoing mutual recognition/decentralised supplement (additional \nform) \n\nOutgoing mutual recognition/decentralised supplement (additional \nstrength) \n\nDecentralised incoming (first additional form) \n\nDecentralised outgoing (first additional form) \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \nMember States \n\n7,140 \n\n4,080 \n\n1,020 \n\n10,200 \n\n6,120 \n\n10,200 \n\n26,520 \n\n7,140 \n\n1,020 \n\n1,530 \n\n7,140 \n\n2,040 \n\n1,020 \n\n3,060 \n\n1,020 \n\n10,200 \n\n26,520 \n\n7,140 \n\n3,060 \n\n1,020 \n\n1,530 \n\n \n \n \n \n \n \n\fSwitching applications \n\nSwitching applications \n\nFees for parallel import licences \n\nApplication fee - per country at the same time or by \nvariation \n\nEach additional strength per country \n\nEach additional form per country \n\nParallel imports - dual pack registration \n\nDual pack registration of parallel imports - each additional \nstrength or form \n\nParallel imports where the originator is not on the Irish \nmarket \n\nChange of ownership per product range \n\nFees for variations to national marketing authorisations \n\nType IB variation \n\nType IB variation - reduced rate \n\nType II complex variation \n\nType II complex variation – reduced rate \n\nType II standard variation \n\nType II standard variation - reduced rate \n\nNotifications under Article 61(3) of Directive 2001/83/ EC \n\nNotifications under Article 61(3) of Directive 2001/83/EC - reduced \nrate \n\nMultiple variations capped fee (per product range) \n\nMultiple variations capped fee (per product) \n\nWorksharing capped fee \n\n[654] 13 \n\n5,200 \n\n1,870 \n\n555 \n\n555 \n\n935 \n\n555 \n\n5,620 \n\n590 \n\n525 \n\n265 \n\n2,920 \n\n 570 \n\n570 \n\n285 \n\n280 \n\n140 \n\n5,395 \n\n3,485 \n\n5,845 \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f14 [654] \n\nFees for variations to marketing authorisations under mutual recognition \nprocedure and decentralised procedure \n\nType IA variation outgoing mutual recognition / decentralised \nsupplement \n\nType IB variation outgoing mutual recognition / decentralised \nsupplement \n\nType IB variation - mutual recognition incoming \n\nType IB variation - mutual recognition incoming - reduced rate \n\nType II complex variation - outgoing mutual recognition / \ndecentralised supplement \n\nType II complex variation - mutual recognition incoming \n\nType II complex variation – mutual recognition incoming – reduced \nrate \n\nType II standard variation - mutual recognition incoming \n\nType II standard variation - mutual recognition incoming - reduced \nrate \n\nType II standard variation - outgoing mutual recognition / \ndecentralised supplement \n\nNotifications made under Article 61(3) of Directive 2001/83/EC \n\nNotifications made under Article 61(3) of Directive 2001/83/EC – \nreduced rate \n\n280 \n\n390 \n\n380 \n\n195 \n\n590 \n\n2,020 \n\n380 \n\n380 \n\n195 \n\n380 \n\n280 \n\n140 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[654] 15 \n\nFees for the granting of a marketing authorisation on transfer to another \ncompany \n\nChange of ownership - related company – 1st marketing \nauthorisation within a range \n\nChange of ownership - related company – each additional marketing \nauthorisation within a range \n\nChange of ownership - non-related company – 1st marketing \nauthorisation within a range \n\nChange of ownership - non-related company – each additional \nmarketing authorisation within a range \n\n1,010 \n\n360 \n\n1,480 \n\n360 \n\nOther fees relating to the granting of marketing authorisations \n\nService item \n\nNotification to become a listed organisation \n\nNotification Fee \n\nFees for applications for wholesaler’s authorisations \n\nApplication fee \n\nVariation to authorisation - minor site technical \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\n685 \n\n10 \n\n625 \n\n450 \n\n245 \n\n675 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f16 [654] \n\nFees for applications for manufacturer’s authorisations \n\nApplication fee \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nVariation to authorisation – investigational medicinal product – fast \ntrack \n\n2,080 \n\n310 \n\n865 \n\n1,225 \n\nFees for applications in relation to brokers register and active substances \nregister \n\nRegistration fee – importers and distributors of active substances and \nbrokers \n\nRegistration fee – manufacturers of active substances \n\nImmediate notification of a change which may impact on the quality \nor safety of the active substances \n\nNotification of an administrative change to the active substances \nregister \n\nNotification of any change to the brokers register \n\nFees for applications for organ establishment authorisations \n\nApplication charge \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nAppeal to amend/revoke an authorisation \n\nScientific opinion on the non-viability of the cells/tissue, donation, \nprocurement testing \n\n280 \n\n495 \n\n865 \n\n155 \n\n155 \n\n2,080 \n\n310 \n\n865 \n\n560 \n\n 3,000 \n\n \n \n \n \n \n \n \n \n \n \n \n\f1,245 \n\n2,080 \n\n 410 \n\n625 \n\n165 \n\n310 \n\n25 \n\n760 \n\n1,140 \n\nFees for transferring of authorisation/registration to another company \n\n[654] 17 \n\nManufacturer’s authorisation and organ establishment \nauthorisation \n\nRelated company \n\nUnrelated company \n\nWholesaler’s authorisation, registration on brokers register and \nregistration on active substances register \n\nRelated company \n\nUnrelated company \n\nFees for applications in relation to cosmetic products \n\nCertificates of free sale – standard (4 certificates per request) \n\nCertificates of free sale – fast track (4 certificates per request) \n\nDuplicate certificates of free sale – each (available at time of initial \nrequest) \n\nFees for applications in relation to homeopathic medicinal products \n\nNew national / decentralised registration standard charge - single \nstock \n\nNew national / decentralised registration standard charge - 2 or more \nstocks \n\nNew application - national rules scheme standard fee - single stock \n\n1,140 \n\nNew application - national rules scheme standard fee - 2 or more \nstocks \n\n1,685 \n\nMutual recognition incoming application standard fee - single stock \n\nMutual recognition incoming application standard fee - 2 or more \nstocks \n\nOutgoing mutual recognition / decentralised supplement \n\nNational variation – registration and national rules scheme \n\nNational variation – reduced rate – registrations and national rules \n\n510 \n\n760 \n\n635 \n\n380 \n\n190 \n\n \n \n \n \n \n \n \n \n \n \n\f18 [654] \n\nscheme \n\nMutual recognition incoming variation \n\nMutual recognition incoming variation - reduced rate \n\nVariation – outgoing mutual recognition / decentralised supplement \n\nBulk variation for multiple changes to the masterfile \n\n255 \n\n125 \n\n190 \n\n2,290 \n\nFees for applications in relation to traditional herbal medicinal products \n\nNational applications for certificates of traditional-use \nregistration \n\nNational application \n\nNational application where there is a monograph \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nExtension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength \n\nEach additional strength (same time) \n\n5,495 \n\n3,370 \n\n4,575 \n\n590 \n\n3,655 \n\n5,495 \n\n4,575 \n\n2,480 \n\n590 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\fApplications for certificates of traditional-use registration under \nmutual recognition procedure and decentralised procedure \n\nMutual recognition incoming \n\nMutual recognition incoming - each additional form (same time) \n\n[654] 19 \n\n3,840 \n\n2,570 \n\nMutual recognition incoming - each additional strength (same time) \n\n590 \n\nOutgoing mutual recognition / decentralised supplement \n\nDecentralised outgoing/incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n4,995 \n\n5,495 \n\n4,575 \n\n590 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f20 [654] \n\nTraditional herbal medicinal products – national variations \n\nType IB variation – national \n\nType IB variation – reduced rate \n\nType II standard variation \n\nType II standard variation – reduced rate \n\nType II complex variation \n\nBulk variation for multiple changes \n\nTraditional herbal medicinal products – mutual recognition \nvariations \n\nType IB variation – mutual recognition incoming \n\nType IB variation – mutual recognition incoming - reduced rate \n\nType IB variation – outgoing mutual recognition supplement \n\nType II standard – mutual recognition incoming \n\nType II standard – mutual recognition incoming - reduced rate \n\nType II standard – outgoing mutual recognition supplement \n\nType II complex – mutual recognition incoming \n\nType II complex – outgoing mutual recognition supplement \n\nFees for export certificates and certification of documents \n\nStandard \n\nFast track \n\nAnnual maintenance fees \n\nMarketing authorisations and registrations \n\nFirst 10 marketing authorisations \n\n420 \n\n215 \n\n450 \n\n225 \n\n2,360 \n\n4,720 \n\n305 \n\n155 \n\n310 \n\n305 \n\n155 \n\n305 \n\n1,615 \n\n470 \n\n165 \n\n310 \n\n730 \n\n \n \n \n \n \n \n \n \n \n \n\fAdditional marketing authorisation \n\nDormant marketing authorisation \n\nParallel import licence \n\nParallel import licence - Dual pack \n\nCertificate of registration - homeopathic medicinal products \n\nCertificate of traditional-use registration - traditional herbal \nmedicinal products \n\nManufacturer’s authorisations \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\nHomeopathic manufacturing site \n\nWholesaler’s authorisations \n\nLarge full line \n\nMedium full line / short line \n\nSmall short line \n\nMinor site / Procure & supply \n\nActive substances register \n\nActive substances distributor \n\nActive substances importer \n\nActive substances manufacturer \n\n[654] 21 \n\n910 \n\n463 \n\n125 \n\n60 \n\n60 \n\n125 \n\n22,000 \n\n15,000 \n\n10,000 \n\n4,500 \n\n1,125 \n\n3,115 \n\n1,770 \n\n675 \n\n450 \n\n280 \n\n560 \n\n1,125 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f22 [654] \n\nOrgan establishment authorisations \n\nMajor establishment (more than 250 employees) \n\nLarge establishment (150-250 employees) \n\nMedium establishment (50-149 employees) \n\nSmall establishment (less than 50 employees) \n\nMinor establishment (less than 5 employees) \n\n18,730 \n\n12,485 \n\n8,325 \n\n4,160 \n\n1,125 \n\nFees in relation to protection of animals used for scientific purposes \n\nProject fees \n\nProject application without ethical approval \n\nFast track project application \n\nBreeder/Supplier/User Authorisation fees \n\nBand 1: Small establishment with no animal facilities or \nestablishment with 1-3 individual authorisation holders \n\nBand 2: Establishment with 4-10 individual authorisation holders \n\nBand 3: Establishment with 11-20 individual authorisation holders \n\n2,100 \n\n2,100 \n\n305 \n\n605 \n\n935 \n\nBand 4: Establishment with 21-50 individual authorisation holders \n\n1,760 \n\nBand 5: Establishment with 51-100 individual authorisation holders \n\n3,575 \n\nBand 6: Establishment with 101-150 individual authorisation holders \n\n6,050 \n\nBand 7: Establishment with 151 – 200 individual authorisation \nholders \n\n8,800 \n\nBand 8: Establishment with >201 individual authorisation holders \n\n11,550 \n\n \n \n \n \n \n \n \n \n \n\fIndividual authorisation fees \n\nApplication fee \n\nAnnual fee \n\nOnce-off authorisation - procedural training for a period of two \nmonths or less (reduced fee) \n\nFees for follow-up inspections \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\n[654] 23 \n\n295 \n\n295 \n\n100 \n\n1,675 \n\n240 \n\nInspection/Audit fees (other than inspections in relation to the protection \nof animals used for scientific purposes) \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\nInspection booking fee \n\nEnforcement fees \n\nManufacturers \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\nWholesalers \n\nLarge full line \n\nMedium full line / short line \n\n1,675 \n\n240 \n\n1,000 \n\n2,695 \n\n2,025 \n\n675 \n\n225 \n\n675 \n\n225 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f24 [654] \n\nMarketing authorisation / parallel import licence holders \n\n> 50 marketing authorisations / parallel import licences \n\n31-50 marketing authorisations / parallel import licences \n\n16-30 marketing authorisations / parallel import licences \n\n6-15 marketing authorisations / parallel import licences \n\n3,540 \n\n1,125 \n\n675 \n\n225 \n\n(Note: Companies classed as both manufacturer and wholesaler are charged the \nhigher of the two applicable charges. Marketing authorisation holders pay the \nmarketing authorisation holder fee \nto any manufacturer’s \nauthorisation / wholesaler’s authorisation fee.) \n\nin addition \n\nFees in relation to medical devices \n\nManufacturer / manufacturing facility located in Ireland – annual fees \n\nManufacturer or manufacturing facility - with more than 150 \nemployees \n\n30,600 \n\nManufacturer or manufacturing facility - with 100-150 employees \n\n20,400 \n\nManufacturer or manufacturing facility - with 50-99 employees \n\nManufacturer or manufacturing facility - with 16-49 employees \n\nManufacturer or manufacturing facility - with 5-15 employees \n\nManufacturer or manufacturing facility - with less than 5 employees \nor annual turnover of less than €500,000 \n\n15,300 \n\n 5,100 \n\n 1,275 \n\n250 \n\n(Note: Where one entity has multiple manufacturing facilities based in the \nState, the entity will be charged per manufacturing facility to a maximum fee \nof €61,200.) \n\nAuthorised Representatives – annual fees \n\nI Authorised Representative – \nlow \nthat manufactures \n\nType \nmanufacturer \nmanufacturer) \n\nrepresenting a non-EU \n(fee per \nrisk* devices \n\n1,100 \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[654] 25 \n\n – representing a non-EU \nType II Authorised Representative \nmanufacturer that manufactures high risk** devices or a mix of high \nrisk** & low risk* devices (fee per manufacturer) \n\n1,500 \n\nCap on type I Authorised Representative \n\nCap on type II Authorised Representative \n\n5,500 \n\n7,500 \n\n(Note: * low risk devices means Class I general medical devices (as described \nin Council Directive 93/42/EEC of 14 June 199314 (‘MDD’) / Regulation (EU) \n2017/745 of the European Parliament and of the Council of 5 April 2017 15 \n(‘MDR’)) and/or general category IVDs (as described in Directive 98/79/EC of \nthe European Parliament and of the Council of 27 October 199816 (‘IVDD’)) / \nClass A (as described in Regulation (EU) 2017/746 of the European Parliament \nand of the Council of 5 April 201717 (‘IVDR’).) \n\n(Note: ** high risk devices means Class IIa, IIb, III general medicinal devices \n(as described in MDD/MDR), active implantable medicinal devices, self-test \nIVD, Annex II IVD (as described in IVDD) or Class B, C and D (as described \nin IVDR) \n\nDistributors and Importers – annual fees \n\nLarge distributor/importer (turnover greater than €15 million) \n\nMedium distributor/importer (turnover €3-€15 million) \n\nSmall distributor/importer (turnover under €3 million) \n\nDistributor/importer turnover less than €500,000 \n\n4,590 \n\n2,550 \n\n1,275 \n\n 250 \n\nAdditional supplement – Entities acting as both a distributor and \nimporter where turnover is more than €500,000 \n\n1,000 \n\nAdditional supplement – Entities acting as both a distributor and \nimporter where turnover is less than €500,000 \n\n250 \n\nNotified Body – annual fees \n\n 5,100 \n\nSummary evaluation review fees \n\n14 OJ L169, 12.7.1993, p.1 \n15 OJ L117, 5.5.2017, p.1 \n16 OJ L331, 7.12.1998, p.1 \n17 OJ L117, 5.5.2017, p.176 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f26 [654] \n\nMedical devices using starting materials for which a TSE certificate \nof suitability has been submitted \n\nMedical devices using starting materials for which a TSE certificate \nof suitability has not been submitted \n\nCertificates of free sale or letters confirming the location of the \nmanufacturing facility in Ireland for medical devices \n\nCertificate of free sale/letter confirming the location of the \nmanufacturing facility in Ireland (4 certificates per request) \n\nEach additional certificate of free sale/letter confirming the location \nof the manufacturing facility in Ireland – (available at time of \nrequest) \n\n2,500 \n\n5,000 \n\n255 \n\n25 \n\nGIVEN under my Official Seal, \n\n17 December, 2020. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[654] 27", "text_norm": "schedule column 1 column 2 fee national application marketing authorisation eur complex dossier national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - complex national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - standard national application additional form (same time) additional strength (same time) additional drug master file submitted subsequent extension application first additional form additional form (same time) first additional strength (existing form) additional strength (same time) additional drug master file submitted 20 400 7 140 1 020 4 080 15 300 7 140 1 020 4 080 10 200 7 140 1 020 4 080 10 200 7 140 3 060 1 020 4 080 fee application marketing authorisation using mutual recognition procedure decentralised procedure complex dossier mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state reduced dossier - complex mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state 654 11 14 280 5 100 1 020 15 300 15 300 20 400 51 000 7 140 1 020 1 530 10 200 5 100 1 020 15 300 10 200 15 300 40 800 7 140 1 020 1 530 12 654 reduced dossier - standard mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state subsequent extension application mutual recognition incoming (first additional form) mutual recognition incoming (first additional strength) mutual recognition incoming (subsequent additional strength) outgoing mutual recognition decentralised supplement (additional form) outgoing mutual recognition decentralised supplement (additional strength) decentralised incoming (first additional form) decentralised outgoing (first additional form) additional form (same time) first additional strength (existing form) additional strength (same time) additional supplement 15 concerned member state 7 140 4 080 1 020 10 200 6 120 10 200 26 520 7 140 1 020 1 530 7 140 2 040 1 020 3 060 1 020 10 200 26 520 7 140 3 060 1 020 1 530 switching application switching application fee parallel import licence application fee - per country time variation additional strength per country additional form per country parallel import - dual pack registration dual pack registration parallel import - additional strength form parallel import originator irish market change ownership per product range fee variation national marketing authorisation type ib variation type ib variation - reduced rate type ii complex variation type ii complex variation - reduced rate type ii standard variation type ii standard variation - reduced rate notification article 61(3) directive 2001 83 ec notification article 61(3) directive 2001 83 ec - reduced rate multiple variation capped fee (per product range) multiple variation capped fee (per product) worksharing capped fee 654 13 5 200 1 870 555 555 935 555 5 620 590 525 265 2 920 570 570 285 280 140 5 395 3 485 5 845 14 654 fee variation marketing authorisation mutual recognition procedure decentralised procedure type ia variation outgoing mutual recognition decentralised supplement type ib variation outgoing mutual recognition decentralised supplement type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate type ii complex variation - outgoing mutual recognition decentralised supplement type ii complex variation - mutual recognition incoming type ii complex variation - mutual recognition incoming - reduced rate type ii standard variation - mutual recognition incoming type ii standard variation - mutual recognition incoming - reduced rate type ii standard variation - outgoing mutual recognition decentralised supplement notification made article 61(3) directive 2001 83 ec notification made article 61(3) directive 2001 83 ec - reduced rate 280 390 380 195 590 2 020 380 380 195 380 280 140 654 15 fee granting marketing authorisation transfer another company change ownership - related company - 1st marketing authorisation within range change ownership - related company - additional marketing authorisation within range change ownership - non-related company - 1st marketing authorisation within range change ownership - non-related company - additional marketing authorisation within range 1 010 360 1 480 360 fee relating granting marketing authorisation service item notification become listed organisation notification fee fee application wholesaler authorisation application fee variation authorisation - minor site technical variation authorisation - administrative variation authorisation - technical 685 10 625 450 245 675 16 654 fee application manufacturer authorisation application fee variation authorisation - administrative variation authorisation - technical variation authorisation - investigational medicinal product - fast track 2 080 310 865 1 225 fee application relation broker register active substance register registration fee - importer distributor active substance broker registration fee - manufacturer active substance immediate notification change may impact quality safety active substance notification administrative change active substance register notification change broker register fee application organ establishment authorisation application charge variation authorisation - administrative variation authorisation - technical appeal amend revoke authorisation scientific opinion non-viability cell tissue donation procurement testing 280 495 865 155 155 2 080 310 865 560 3 000 1 245 2 080 410 625 165 310 25 760 1 140 fee transferring authorisation registration another company 654 17 manufacturer authorisation organ establishment authorisation related company unrelated company wholesaler authorisation registration broker register registration active substance register related company unrelated company fee application relation cosmetic product certificate free sale - standard (4 certificate per request) certificate free sale - fast track (4 certificate per request) duplicate certificate free sale - (available time initial request) fee application relation homeopathic medicinal product new national decentralised registration standard charge - single stock new national decentralised registration standard charge - 2 stock new application - national rule scheme standard fee - single stock 1 140 new application - national rule scheme standard fee - 2 stock 1 685 mutual recognition incoming application standard fee - single stock mutual recognition incoming application standard fee - 2 stock outgoing mutual recognition decentralised supplement national variation - registration national rule scheme national variation - reduced rate - registration national rule 510 760 635 380 190 18 654 scheme mutual recognition incoming variation mutual recognition incoming variation - reduced rate variation - outgoing mutual recognition decentralised supplement bulk variation multiple change masterfile 255 125 190 2 290 fee application relation traditional herbal medicinal product national application certificate traditional-use registration national application national application monograph additional form (same time) additional strength (same time) additional drug master file submitted extension application first additional form additional form (same time) first additional strength additional strength (same time) 5 495 3 370 4 575 590 3 655 5 495 4 575 2 480 590 application certificate traditional-use registration mutual recognition procedure decentralised procedure mutual recognition incoming mutual recognition incoming - additional form (same time) 654 19 3 840 2 570 mutual recognition incoming - additional strength (same time) 590 outgoing mutual recognition decentralised supplement decentralised outgoing incoming additional form (same time) additional strength (same time) 4 995 5 495 4 575 590 20 654 traditional herbal medicinal product - national variation type ib variation - national type ib variation - reduced rate type ii standard variation type ii standard variation - reduced rate type ii complex variation bulk variation multiple change traditional herbal medicinal product - mutual recognition variation type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate type ib variation - outgoing mutual recognition supplement type ii standard - mutual recognition incoming type ii standard - mutual recognition incoming - reduced rate type ii standard - outgoing mutual recognition supplement type ii complex - mutual recognition incoming type ii complex - outgoing mutual recognition supplement fee export certificate certification document standard fast track annual maintenance fee marketing authorisation registration first 10 marketing authorisation 420 215 450 225 2 360 4 720 305 155 310 305 155 305 1 615 470 165 310 730 additional marketing authorisation dormant marketing authorisation parallel import licence parallel import licence - dual pack certificate registration - homeopathic medicinal product certificate traditional-use registration - traditional herbal medicinal product manufacturer authorisation major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) homeopathic manufacturing site wholesaler authorisation large full line medium full line short line small short line minor site procure supply active substance register active substance distributor active substance importer active substance manufacturer 654 21 910 463 125 60 60 125 22 000 15 000 10 000 4 500 1 125 3 115 1 770 675 450 280 560 1 125 22 654 organ establishment authorisation major establishment (more 250 employees) large establishment (150-250 employees) medium establishment (50-149 employees) small establishment (less 50 employees) minor establishment (less 5 employees) 18 730 12 485 8 325 4 160 1 125 fee relation protection animal used scientific purpose project fee project application without ethical approval fast track project application breeder supplier user authorisation fee band 1 small establishment animal facility establishment 1-3 individual authorisation holder band 2 establishment 4-10 individual authorisation holder band 3 establishment 11-20 individual authorisation holder 2 100 2 100 305 605 935 band 4 establishment 21-50 individual authorisation holder 1 760 band 5 establishment 51-100 individual authorisation holder 3 575 band 6 establishment 101-150 individual authorisation holder 6 050 band 7 establishment 151 - 200 individual authorisation holder 8 800 band 8 establishment 201 individual authorisation holder 11 550 individual authorisation fee application fee annual fee once-off authorisation - procedural training period two month le (reduced fee) fee follow-up inspection per day (per member inspection team) part day (per hour per member inspection team) 654 23 295 295 100 1 675 240 inspection audit fee (other inspection relation protection animal used scientific purposes) per day (per member inspection team) part day (per hour per member inspection team) inspection booking fee enforcement fee manufacturer major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) wholesaler large full line medium full line short line 1 675 240 1 000 2 695 2 025 675 225 675 225 24 654 marketing authorisation parallel import licence holder 50 marketing authorisation parallel import licence 31-50 marketing authorisation parallel import licence 16-30 marketing authorisation parallel import licence 6-15 marketing authorisation parallel import licence 3 540 1 125 675 225 (note company classed manufacturer wholesaler charged higher two applicable charge marketing authorisation holder pay marketing authorisation holder fee manufacturer authorisation wholesaler authorisation fee.) addition fee relation medical device manufacturer manufacturing facility located ireland - annual fee manufacturer manufacturing facility - 150 employee 30 600 manufacturer manufacturing facility - 100-150 employee 20 400 manufacturer manufacturing facility - 50-99 employee manufacturer manufacturing facility - 16-49 employee manufacturer manufacturing facility - 5-15 employee manufacturer manufacturing facility - le 5 employee annual turnover le eur500 000 15 300 5 100 1 275 250 (note one entity multiple manufacturing facility based state entity charged per manufacturing facility maximum fee eur61 200.) authorised representative - annual fee authorised representative - low manufacture type manufacturer manufacturer) representing non-eu (fee per risk device 1 100 654 25 - representing non-eu type ii authorised representative manufacturer manufacture high risk device mix high risk low risk device (fee per manufacturer) 1 500 cap type authorised representative cap type ii authorised representative 5 500 7 500 (note low risk device mean class general medical device (as described council directive 93 42 eec 14 june 199314 ( mdd ) regulation (eu) 2017 745 european parliament council 5 april 2017 15 ( mdr )) general category ivds (as described directive 98 79 ec european parliament council 27 october 199816 ( ivdd )) class (as described regulation (eu) 2017 746 european parliament council 5 april 201717 ( ivdr ).) (note high risk device mean class iia iib iii general medicinal device (as described mdd mdr) active implantable medicinal device self-test ivd annex ii ivd (as described ivdd) class b c (as described ivdr) distributor importer - annual fee large distributor importer (turnover greater eur15 million) medium distributor importer (turnover eur3-eur15 million) small distributor importer (turnover eur3 million) distributor importer turnover le eur500 000 4 590 2 550 1 275 250 additional supplement - entity acting distributor importer turnover eur500 000 1 000 additional supplement - entity acting distributor importer turnover le eur500 000 250 notified body - annual fee 5 100 summary evaluation review fee 14 oj l169 12.7.1993 p.1 15 oj l117 5.5.2017 p.1 16 oj l331 7.12.1998 p.1 17 oj l117 5.5.2017 p.176 26 654 medical device using starting material tse certificate suitability submitted medical device using starting material tse certificate suitability submitted certificate free sale letter confirming location manufacturing facility ireland medical device certificate free sale letter confirming location manufacturing facility ireland (4 certificate per request) additional certificate free sale letter confirming location manufacturing facility ireland - (available time request) 2 500 5 000 255 25 given official seal 17 december 2020 stephen donnelly minister health 654 27", "start_char": 14290, "end_char": 33506, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
{"doc_id": "si-2020-0654-explanatory-note", "parent_doc_id": "si-2020-0654", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 654 of 2020", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2020, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninstrument.) \n\nThe purpose of these Regulations is to provide for the revision of fees payable \nto the Health Products Regulatory Authority (formerly the Irish Medicines \nBoard) pursuant to Section 13 of the Irish Medicines Board Act 1995. \n\nThese Regulations revoke the Health Products Regulatory Authority (Fees) \nRegulations 2019 (S.I. No. 700 of 2019). \n\nThese Regulations may be cited as the Health Products Regulatory Authority \n(Fees) Regulations 2020. \n\n \n \n \n \n \n \n \n\f28 [654] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€ 6.50 \n\n(DH-162) 75. 12/20. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal instrument.) purpose regulation provide revision fee payable health product regulatory authority (formerly irish medicine board) pursuant section 13 irish medicine board act 1995 regulation revoke health product regulatory authority (fees) regulation 2019 (s.i no 700 2019) regulation may cited health product regulatory authority (fees) regulation 2020 28 654 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur 6.50 (dh-162) 75 12 20 propylon", "start_char": 33506, "end_char": 34540, "source_path": "downloads\\2020\\2020_0653.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c176c38de67e926857002e0302d3ed99391a89038a09d90c294941e4ed12b9c6", "cross_refs": []}
